Physician profile
Amy Lee Kinter
NPI 1649717398
$3,473.04
in general payments reported to CMS, 2019-2025
44 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.62 · 2022: $916 · 2023: $244 · 2024: $857 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412 · Education: $91.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.45 |
| Education | $91.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $386.95 | 2022-2024 | Zeposia, Eliquis |
| Janssen Biotech, INC. | $252.05 | 2024-2025 | Erleada, Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.63 | 2024-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $245.26 | 2024-2025 | |
| Amgen INC. | $228.59 | 2021-2025 | Repatha |
| Merck Sharp & Dohme LLC | $200.02 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| Pfizer INC. | $188.53 | 2022-2025 | |
| Evoke Pharma, INC. | $141.63 | 2024 | |
| Janssen Pharmaceuticals, INC | $128.15 | 2022-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $115.96 | 2024-2025 | Entyvio |
| Lilly USA, LLC | $103.12 | 2024-2025 | Omvoh, Verzenio, Jaypirca |
| Qol Medical, LLC | $102.63 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $98.17 | 2024-2025 | Dupixent, Lynozyfic |
| Bayer Healthcare Pharmaceuticals INC. | $97.11 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $96.38 | 2022-2025 | Enhertu, Farxiga |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.52 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $63.67 | 2021-2022 | |
| Madrigal Pharmaceuticals | $60.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Alnylam Pharmaceuticals INC. | $51.29 | 2022 | |
| Celltrion USA INC. | $37.05 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $34.08 | 2025 | Enhertu, Datroway |
| Pharmacosmos Therapeutics INC. | $30.20 | 2025 | Monoferric |
| Tempus Ai, INC | $29.74 | 2025 | Xt Cdx |
| Actelion Pharmaceuticals US, INC. | $29.73 | 2022 | |
| Genzyme Corporation | $28.85 | 2025 | |
| Exelixis INC. | $24.79 | 2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $24.52 | 2025 | |
| Incyte Corporation | $24.13 | 2025 | Jakafi |
| Syndax Pharmaceuticals, INC. | $24.00 | 2025 | |
| Genmab U.S., INC. | $22.58 | 2025 | Tivdak |
| Celgene Corporation | $22.54 | 2025 | Reblozyl |
| Azurity Pharmaceuticals, INC. | $20.19 | 2025 | Vivimusta, Danziten |
| Deciphera Pharmaceuticals INC. | $19.95 | 2025 | Qinlock |
| Glaxosmithkline, LLC. | $19.37 | 2025 | Ojjaara |
| Caris Mpi, INC. | $19.15 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $19.15 | 2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $18.88 | 2025 | |
| Boston Scientific Corporation | $18.80 | 2023 | Superion Indirect Decompression System |
| Aimmune Therapeutics, INC. | $18.78 | 2025 | Vowst |
| Ucb, INC. | $18.75 | 2023 | |
| Braintree Laboratories, INC. | $17.81 | 2025 | Sutab, Suflave |
| Ardelyx, INC. | $17.11 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $14.31 | 2023 | Ultomiris |
| Gilead Sciences, INC. | $14.16 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Kinter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.